Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

enhance the immune system’s ability to fight cancer by blocking the programmed cell death protein 1 (PD-1) pathway. These drugs have transformed treatment for lung cancer, melanoma, head and neck ...

Lung cancer and malignant melanoma are major healthcare ... PD-L1 is a critical biomarker for potential response to anti-PD-1 therapies, which are revolutionizing the treatment of cancer.

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...

In addition to lung cancer, we have observed encouraging efficacy signals in ... IBI363 is a first-in-class drug candidate independently developed by Innovent Biologics. It is a PD-1/IL-2 bispecific ...

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown ... in a Chinese PD-L1-positive non-small cell lung cancer (NSCLC) population. That led some market ...